Nasal Polyps and Asthma: The Unified Airway Connection

What Are Nasal Polyps?

Nasal polyps are soft, noncancerous growths that develop from the mucous membrane lining the nose and paranasal sinuses. When the sinus lining becomes chronically inflamed, it swells and eventually prolapses downward into the nasal cavity as smooth, teardrop-shaped growths. Small polyps may produce no symptoms at all. Large or numerous polyps can block nasal airflow on both sides, eliminate the sense of smell, and make breathing through the nose almost impossible.

The full medical condition is called chronic rhinosinusitis with nasal polyps (CRSwNP) -- defined by nasal and sinus inflammation that has persisted for at least 12 weeks, confirmed by endoscopy showing polyps and by CT imaging. The "chronic" designation separates it from short-term sinus infections, which do not typically cause polyps.

In the United States, the large majority of nasal polyps are eosinophilic: the tissue is packed with eosinophils, mast cells, and type 2 cytokines including interleukin-4 (IL-4), interleukin-5 (IL-5), and interleukin-13 (IL-13). These are the identical immune mediators that drive eosinophilic asthma in the bronchi. This biological overlap is not coincidental -- it is the molecular foundation of the unified airway model and the scientific rationale for treating both conditions with a single biologic agent.

The Unified Airway: One Inflammatory System

For decades, pulmonologists treated asthma and ENT specialists treated nasal polyps as if the two conditions were entirely separate. The unified airway theory changed that paradigm. It holds that the upper airway (nose, sinuses, nasopharynx) and lower airway (trachea, bronchi, bronchioles, alveoli) constitute one continuous physiological and immunological unit -- connected by mucosal continuity, shared circulating immune cells, inflammatory cytokines that travel freely between the two regions, and neurological reflexes that link nasal irritation to bronchospasm.

Six Mechanisms Linking Nasal Polyps to Asthma

How Common Is the Overlap?

CRSwNP affects approximately 2-4% of the general adult population. Among people with asthma, the prevalence is dramatically higher and rises with disease severity:

The relationship is bidirectional. Among patients first diagnosed with CRSwNP for nasal symptoms, asthma develops in 20-40% over subsequent years -- particularly in those with elevated blood or tissue eosinophil counts. This makes comprehensive airway screening essential for any patient presenting with either condition.

AERD: When Nasal Polyps, Asthma, and Aspirin Sensitivity Converge

Aspirin-Exacerbated Respiratory Disease (AERD), historically called Samter's Triad, is defined by three co-occurring conditions: asthma, chronic rhinosinusitis with nasal polyps, and acute respiratory reactions triggered by aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs). AERD affects roughly 9-10% of adults with asthma overall and up to 30% of those with severe or steroid-dependent disease.

The mechanism is prostaglandin-leukotriene imbalance. Aspirin and NSAIDs inhibit cyclooxygenase-1 (COX-1), blocking the conversion of arachidonic acid into prostaglandins. With COX-1 blocked, arachidonic acid is shunted through the 5-lipoxygenase (5-LOX) pathway, causing a massive surge in cysteinyl leukotrienes (LTC4, LTD4, LTE4) -- potent bronchoconstrictors and promoters of eosinophilic inflammation. Patients experience rhinorrhea, severe nasal congestion, wheezing, chest tightness, and sometimes urticaria within 30-120 minutes of ingesting a COX-1-inhibiting drug.

Distinguishing features of AERD compared with standard allergic asthma:

• Rapidly recurrent nasal polyps that regrow within weeks to months after sinus surgery
• Profound anosmia (loss of smell) that may be nearly complete and precedes diagnosis by years
• Alcohol sensitivity -- beer and wine trigger nasal and respiratory symptoms in many AERD patients due to yeast-derived prostaglandins
• Elevated urinary leukotriene E4 at baseline, not only after aspirin challenge
• Poor response to allergen immunotherapy (the process is not IgE-dependent)
• Notable sensitivity to aspirin, ibuprofen, naproxen, ketorolac, and other COX-1 inhibitors; acetaminophen and celecoxib are generally tolerated

For full management details including aspirin desensitization protocols, see our dedicated page on AERD / Samter's Triad.

Recognizing the Symptoms: Upper and Lower Airway Together

Many patients with combined CRSwNP and asthma seek care only for their breathing -- unaware that undertreated nasal disease is actively driving their lower airway symptoms. Mapping the full bilateral symptom picture guides more effective, coordinated treatment:

Diagnosis: Building the Full Airway Picture

Confirming CRSwNP alongside asthma requires evaluation of both airway regions and an inflammatory profile that guides biologic selection. At Advanced Asthma Clinic in Plantation, FL, we coordinate pulmonary assessment with ENT referral to build a complete picture for each patient.

Upper Airway Assessment

• Nasal endoscopy: Flexible or rigid thin-camera visualization of the nasal passages and middle meatus confirms the presence, bilateral extent, and size grade of polyps. Performed in-office under local decongestant spray.
• CT sinuses (without contrast): Provides a three-dimensional map of polyp distribution, sinus opacification, and bony anatomy. The Lund-Mackay CT score quantifies disease extent and serves as a baseline for surgical planning and biologic response tracking.
• Sinonasal Outcome Test (SNOT-22): Validated patient-reported outcome measure for symptom severity and quality of life in CRSwNP -- used to track treatment response at each visit.
• Smell identification testing: Objective olfactory assessment (e.g., University of Pennsylvania Smell Identification Test, Sniffin' Sticks) documents anosmia degree and tracks restoration with dupilumab or surgery.
• Nasal tissue eosinophil count: When polyp tissue is obtained at surgery, eosinophil density above 10 per high-power field confirms eosinophilic CRSwNP and predicts favorable biologic response.

Lower Airway Assessment

• Spirometry with bronchodilator: Measures FEV1, FVC, and FEV1/FVC to confirm obstruction and assess reversibility. See our spirometry guide.
• FeNO (fractional exhaled nitric oxide): Elevated FeNO (>25 ppb) confirms eosinophilic airway inflammation and predicts strong response to type 2-targeting biologics. See FeNO testing.
• Impulse oscillometry (IOS): Detects small airway dysfunction even when spirometry is normal -- valuable in combined disease where both large and small airways may be affected. See our IOS guide.
• Blood eosinophil count: A count above 300 cells/µL strongly supports type 2 disease and guides biologic selection. Above 500 cells/µL indicates high-eosinophilic phenotype with strongest response to anti-IL-5 biologics. See eosinophil count.
• Total serum IgE: Required for omalizumab dosing in allergic asthma; also contextualizes the overall type 2 burden and atopic profile.
• Oral aspirin challenge: In patients with suspected AERD, a graded oral aspirin challenge confirms the diagnosis under monitored clinical conditions. This is performed only at centers with resuscitation capability.

Treatment: Addressing Both Airway Regions

Because CRSwNP and eosinophilic asthma share a common type 2 inflammatory pathway, the most effective management addresses both conditions simultaneously through a coordinated pulmonology and ENT partnership.

Step 1 -- Nasal Corticosteroids and Saline Irrigation

First-line therapy for CRSwNP combines high-volume nasal saline irrigation -- using a rinse bottle, not a small spray -- with daily intranasal corticosteroids such as fluticasone furoate (Flonase Sensimist), mometasone furoate (Nasonex), or budesonide. These reduce local eosinophil density, shrink small-to-moderate polyps, and relieve congestion. They do not eliminate large polyps or restore smell in patients with severe anosmia. For those patients, biologic therapy or surgery is necessary.

Intranasal corticosteroids are distinct from the inhaled corticosteroids (ICS) used for asthma. Both should be maintained concurrently -- treating only one region leaves the other inadequately controlled and allows the shared inflammation to persist.

Step 2 -- Short Oral Corticosteroid Courses

Courses of oral prednisone (typically 5-14 days) produce rapid, dramatic polyp shrinkage and may temporarily restore smell. They are appropriate for acute symptom control or as a bridge before surgery or biologic initiation. However, polyps invariably regrow within weeks to months after steroids are tapered, and repeated courses carry cumulative systemic risks: adrenal suppression, osteoporosis, weight gain, glucose intolerance, and cataracts. Oral steroids are not an acceptable long-term solution for CRSwNP. See our review of oral corticosteroids in asthma.

Step 3 -- Functional Endoscopic Sinus Surgery (FESS)

When medical therapy provides inadequate control, functional endoscopic sinus surgery (FESS) removes polyps and opens the natural drainage pathways of the sinuses under general anesthesia using small endoscopic cameras and instruments introduced through the nostrils. FESS improves nasal airflow, eliminates facial pressure, and temporarily restores smell in many patients. Importantly, studies consistently show that FESS also improves asthma control scores, reduces rescue bronchodilator use, and in some patients reduces oral corticosteroid requirements -- evidence of the unified airway benefit.

The main limitation of FESS for eosinophilic CRSwNP is recurrence: polyps regrow in 40-60% of patients within five years, sometimes within months, and multiple revision surgeries are common. Biologic therapy initiated after FESS substantially extends polyp-free intervals and reduces the need for reoperation.

Step 4 -- Biologic Therapy: Targeting Type 2 Inflammation at the Source

The development of biologic agents targeting type 2 inflammatory cytokines has fundamentally changed outcomes for patients with combined CRSwNP and asthma. By interrupting the shared cytokine cascade upstream, biologics reduce polyp burden, restore olfaction, improve sinus symptom scores, and improve asthma control -- often all simultaneously and with durable effect measured in years rather than weeks.

Dupilumab (Dupixent) -- The Unified Airway Biologic

Dupilumab occupies a unique position: it is the only biologic with concurrent FDA approval for both CRSwNP and moderate-to-severe asthma. By blocking the IL-4 receptor alpha subunit shared by both IL-4 and IL-13, dupilumab interrupts the central type 2 cytokine signaling pathway that drives eosinophilic inflammation in the sinuses and bronchi simultaneously.

Landmark clinical trial results relevant to the combined-disease patient:

• SINUS-52 trial (CRSwNP): 57% reduction in nasal polyp score vs. placebo at 52 weeks; significant restoration of smell scores -- a response rarely achieved by surgery or other medications alone
• QUEST trial (asthma): 46% reduction in severe asthma exacerbation rate vs. placebo; 130 mL improvement in FEV1 in the overall population; larger effects in patients with higher eosinophil counts or FeNO
• Patients with combined CRSwNP and asthma show additive benefit in both organ systems from the same injection

Dupilumab is administered subcutaneously every two weeks after a loading dose. Common side effects include injection-site reactions and conjunctivitis (eye inflammation), which occurs in a minority of patients and typically resolves with ophthalmic drops. See our full guide to dupilumab for asthma.

Mepolizumab (Nucala) -- Anti-IL-5 for High-Eosinophil Disease

Mepolizumab targets IL-5 directly, reducing eosinophil production in the bone marrow and eosinophil survival in tissue. It received FDA approval for CRSwNP in 2021 and has long-standing approval for severe eosinophilic asthma. For patients with blood eosinophils persistently above 300-500 cells/µL and both conditions, mepolizumab provides dual-region benefit through a single monthly subcutaneous injection. See our mepolizumab guide.

Biologic Selection in Combined Disease

When a patient has both CRSwNP and asthma, the biologic selection decision is shaped by:

• Blood eosinophil count: High counts (≥300-500 cells/µL) favor anti-IL-5 agents (mepolizumab, benralizumab) for maximal eosinophil suppression, or dupilumab which also reduces eosinophils via IL-13 blockade
• FeNO level: Elevated FeNO (>25 ppb) confirms IL-13-mediated airway inflammation and predicts strong dupilumab response
• IgE level and allergen sensitization: High IgE with confirmed allergen sensitivity favors omalizumab, now also approved for CRSwNP
• AERD phenotype: Dupilumab shows particularly strong CRSwNP outcomes in AERD patients, who are otherwise difficult to treat
• Prior biologic history: Inadequate response to one biologic class may justify switching to an agent with a different mechanism
• Insurance and prior authorization: Both conditions listed on the prior authorization request can strengthen approval for dual-indication biologics

Our biologic comparison guide and prior authorization support resource provide additional detail on navigating the selection and approval process.

South Florida Considerations

Patients in South Florida and the greater Broward County area face environmental conditions that aggravate both CRSwNP and asthma year-round:

• Perennial high humidity: Relative humidity of 70-90% throughout the year promotes mold growth in indoor environments -- a powerful driver of both nasal and bronchial eosinophilic inflammation. See our guides on asthma and mold and asthma, humidity, and mold in Florida.
• Year-round pollen: Unlike northern climates with distinct seasons, South Florida sees continuous tree, grass, and weed pollen throughout the calendar year. Patients with allergic components to their CRSwNP benefit from perennial allergen avoidance strategies and potentially allergen immunotherapy.
• Air conditioning: Indoor AC systems are essential for comfort but can harbor mold in drain pans and ductwork if not serviced. They also dry the nasal mucosa when humidity drops below 30% indoors -- paradoxically reducing mucociliary clearance.
• Hurricane season (June-November): Storm-related flooding dramatically increases indoor mold load for weeks after events. Patients with CRSwNP and asthma should have a post-storm action plan including nasal rinses, HEPA filtration, and early medical contact. See hurricane season asthma guide.
• Wildfire smoke: Smoke events from Everglades and northern Florida wildfires reach South Florida and acutely worsen both nasal congestion and bronchospasm. See wildfire smoke and asthma Florida.

Coordinated Care at Advanced Asthma Clinic, Plantation FL

At Advanced Asthma Clinic in Plantation, FL, under the direction of Dr. Frank Hull -- a pulmonologist with over 20 years of experience in pulmonary research and severe asthma management -- we evaluate patients with combined nasal polyps and asthma using a comprehensive unified airway approach. Our on-site capabilities include:

• Spirometry with bronchodilator reversibility testing
• Impulse oscillometry (IOS/FOT) for small airway assessment
• FeNO (fractional exhaled nitric oxide) measurement
• Blood eosinophil and total IgE profiling
• ENT referral coordination for nasal endoscopy and CT sinus evaluation
• Biologic therapy initiation and monitoring for CRSwNP and asthma indications
• Prior authorization assistance for dual-indication biologic prescriptions
• Better Breathing Grant program for qualifying patients who need financial assistance accessing treatment (learn more)

If you have been told you have nasal polyps, if you have lost your sense of smell, if your asthma is not controlled despite inhaled medications, or if you react to aspirin or ibuprofen with breathing symptoms -- we encourage you to contact our clinic. The combination of CRSwNP and asthma is eminently treatable when both airway regions are addressed together.